Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BGLC
stocks logo

BGLC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for BioNexus Gene Lab Corp (BGLC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess BioNexus Gene Lab Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BGLC News & Events

Events Timeline

(ET)
2025-12-03
08:50:00
BioNexus Gene Lab Completes Strategic Transaction with Fidelion Diagnostics
select
2025-12-02 (ET)
2025-12-02
08:31:00
BioNexus Enters $500M Equity Purchase Agreement with ARC Group International
select
2025-12-01 (ET)
2025-12-01
08:30:00
BioNexus Signs $2M Exclusive License Agreement with Fidelion for VitaGuard in Southeast Asia
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-02Globenewswire
BioNexus Gene Lab Corp. Secures $500 Million Equity Purchase Agreement with ARC Group
  • Enhanced Financial Flexibility: BioNexus Gene Lab Corp. has entered into a $500 million equity purchase agreement with ARC Group, which is expected to provide long-term capital to support the commercialization of precision oncology diagnostics and CDMO services across Southeast Asia.
  • Strengthened Strategic Partnership: The agreement allows BioNexus to issue shares at its discretion over the next 36 months, enhancing its competitive position in the oncology testing and biologics production sectors.
  • Technology Platform Expansion: The exclusive licensing agreement with Fidelion Diagnostics to commercialize the VitaGuard™ MRD platform will be supported by ARC's funding, facilitating clinical adoption in Malaysia, Singapore, Indonesia, and Thailand.
  • Support for CDMO Transformation: This financing will enable BioNexus to invest in quality system upgrades and manufacturing capacity, aligning its operations with global CDMO standards and enhancing overall business capabilities.
[object Object]
Preview
7.5
10-20Newsfilter
BioNexus Gene Lab Corp Enters Strategic Partnership Agreement with BirchBioMed Inc.

  • Strategic Partnership Announcement: BioNexus Gene Lab Corp (BGLC) has entered a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. to lead a USD $10 million financing round aimed at commercializing Birch's FS2 topical platform in Southeast Asia.

  • Investment and Support Details: BGLC will issue shares to Birch in exchange for equity, while providing market intelligence and regulatory guidance to assist in the commercialization of Birch's products in Malaysia and Singapore.

[object Object]
Preview
4.5
07-31TipRanks
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

  • Stock Market Update: Investors are currently engaged with ongoing stock market news as they reach the midpoint of the week, highlighting significant developments in the market.

  • Further Information: For more detailed insights and updates on stock market trends, readers are encouraged to visit TipRanks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioNexus Gene Lab Corp (BGLC) stock price today?

The current price of BGLC is 4.33 USD — it has decreased -1.59 % in the last trading day.

arrow icon

What is BioNexus Gene Lab Corp (BGLC)'s business?

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

arrow icon

What is the price predicton of BGLC Stock?

Wall Street analysts forecast BGLC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BGLC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioNexus Gene Lab Corp (BGLC)'s revenue for the last quarter?

BioNexus Gene Lab Corp revenue for the last quarter amounts to 2.54M USD, decreased -3.29 % YoY.

arrow icon

What is BioNexus Gene Lab Corp (BGLC)'s earnings per share (EPS) for the last quarter?

BioNexus Gene Lab Corp. EPS for the last quarter amounts to -0.39 USD, decreased -48.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioNexus Gene Lab Corp (BGLC)'s fundamentals?

The market is revising No Change the revenue expectations for BGLC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -14.09%.
arrow icon

How many employees does BioNexus Gene Lab Corp (BGLC). have?

BioNexus Gene Lab Corp (BGLC) has 30 emplpoyees as of December 05 2025.

arrow icon

What is BioNexus Gene Lab Corp (BGLC) market cap?

Today BGLC has the market capitalization of 10.24M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free